The short answer
A clinically important interaction between magnesium carbonate and dabigatran etexilate has not been established by the sources reviewed. Changes in stomach acidity can affect some dabigatran formulations, but a proton-pump-inhibitor study is not evidence for magnesium carbonate. Review the specific antacid or supplement instead of applying an untested timing rule.
What this answer covers
Oral magnesium carbonate with intact adult oral dabigatran etexilate capsules. Other magnesium salts, proton-pump inhibitors and experimental tablets are separate exposures.
- Supplement or preparation
- Magnesium carbonate
- Medication ingredient
- dabigatran etexilate
Why might stomach acidity matter?
Dabigatran etexilate must dissolve and be absorbed before the body converts it to active dabigatran. The marketed capsule uses acid-containing pellets to support dissolution. Magnesium carbonate may be used in antacid products, but that does not show that it has the same effect as a longer-acting acid-suppressing medicine.
What did the formulation study actually find?
Researchers studied an experimental dabigatran etexilate tablet in healthy men after several days of rabeprazole. Drug exposure fell substantially, and the authors emphasized formulation-dependent sensitivity to stomach pH. The study did not administer magnesium carbonate. Its result must not be presented as an observed reduction from a magnesium supplement with the marketed capsule.
What does current capsule labeling say?
The U.S. label reports no appreciable change in trough dabigatran concentrations with proton-pump inhibitors or H2 blockers in the RE-LY trial. That observation also does not directly test magnesium carbonate. Swallow capsules intact; opening them changes exposure. Do not open a capsule, add an extra dose or change anticoagulant treatment to compensate for a suspected interaction.
What is the practical next step?
Show your pharmacist the product ingredients, magnesium amount, antacid purpose and dosing frequency. Kidney function and other medicines also matter to the medication plan. A reliable magnesium-carbonate-specific effect size or separation interval was not found, so individual advice is more appropriate than treating this pair as a proven loss of anticoagulant effectiveness.
Evidence and practical considerations
Absorption & effectiveness
A clinically important interaction between magnesium carbonate and dabigatran etexilate has not been established by the sources reviewed. Changes in stomach acidity can affect some dabigatran formulations, but a proton-pump-inhibitor study is not evidence for magnesium carbonate. Review the specific antacid or supplement instead of applying an untested timing rule.
- Exact scope
- Oral magnesium carbonate with intact adult oral dabigatran etexilate capsules. Other magnesium salts, proton-pump inhibitors and experimental tablets are separate exposures. with adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Medication form and route
- adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Timing or duration
- Concurrent oral use. Source-specific durations are recorded in the evidence entries; no unstudied duration threshold or separation schedule is inferred.
What remains uncertain
- No direct magnesium carbonate/dabigatran clinical study located. Experimental tablet/rabeprazole findings and capsule/PPI observations are not interchangeable with this exact salt. No established timing interval.
Factors that may matter: Exact supplement preparation, dose and additional ingredients; Kidney function, age, bleeding history and other antiplatelet or anticoagulant medicines; Current medication formulation and recent supplement start or stop.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral dabigatran etexilate capsules.
P-gp induction reduces active dabigatran exposure. P-gp inhibition and impaired renal function increase exposure. Capsules must be swallowed intact. RE-LY trough concentrations were not appreciably changed by concomitant PPIs or H2 blockers.
How this applies: Establishes the exact medicine’s mechanism, baseline bleeding precautions and formulation/transport limitations; it does not establish this supplement-specific interaction. Exact scope: Oral magnesium carbonate with intact adult oral dabigatran etexilate capsules. Other magnesium salts, proton-pump inhibitors and experimental tablets are separate exposures.
Named medicine dose adjustments cannot be extrapolated to untested herbs. Label silence about a supplement does not prove compatibility. Capsule results must not be generalized to every formulation.
Source 2: original human pharmacokinetic study
europepmc.org · Source check Sep 10, 2026
Population: 160 healthy men in bioequivalence study; 36 healthy men in gastric-pH study, 35 completing rabeprazole comparison.
Rabeprazole substantially reduced exposure from the experimental tablet; authors emphasize formulation-dependent pH sensitivity. The tested tablet was not taken forward for Japanese approval.
How this applies: Demonstrates formulation-dependent gastric pH effects of rabeprazole on an experimental tablet. It did not test magnesium carbonate or show this salt reduces exposure from marketed capsules. Exact scope: Oral magnesium carbonate with intact adult oral dabigatran etexilate capsules. Other magnesium salts, proton-pump inhibitors and experimental tablets are separate exposures.
No magnesium carbonate, no antacid coadministration and no clinical clot outcome. The experimental tablet’s roughly 70% exposure reduction is not a result for the marketed capsule or magnesium supplements.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current labels and targeted original sources assessed; all current available claims adjudicated and consumer article prepared. Uncertainty and indirect evidence retained. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 0bde91932537e485
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.